Deals help Novavax pay off $22M in debts

Flush from a pair of newly inked collaborations, Novavax has paid off the last of its debt.

Novavax began this year--one of the rockiest in biotech history--with $22 million in convertible debt. But the last $5 million was paid off earlier in the week as the developer cleared the books of debt.

Novavax was able to do that by striking a couple of deals. The developer created a new joint venture with India's Cadila to advance Novavax's virus-like particle vaccine for swine flu in the subcontinent. Cadila agreed to invest $11 million in Novavax in order to set up the venture. And just last month Novavax gained a $3 million equity investment from Spain's Rovi after the two companies agreed to collaborate, using Novavax's technology to advance new vaccines.

- check out the story from the Washington Business Journal

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.